TG Therapeutics raises 2026 revenue guidance after strong Q2 with BRIUMVI sales hitting $228M in the U.S.

TG Therapeutics reported strong second quarter 2026 results with total global revenue of approximately $240 million, including $228 million in U.S. net product revenue from BRIUMVI. The company raised its full year 2026 revenue guidance to about $950 million globally and $890-$905 million for U.S. BRIUMVI sales. Positive Phase 3 trial results and progress in subcutaneous BRIUMVI and new indications like myasthenia gravis and schizophrenia support growth. TG Therapeutics expects continued momentum and upcoming data releases by early 2027.